Purpose

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has EGFR and MET gene changes. Capmatinib and osimertinib are in a class of medications called kinase inhibitors. They work by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving capmatinib, osimertinib, and/or ramucirumab and targeting abnormal gene changes in tumor cells may be effective in shrinking or stabilizing advanced non-small cell lung cancer.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) - Participants must have been assigned to S1900G by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S1900G is determined by the LUNGMAP protocol - Participants must have documentation of NSCLC with a sensitizing EGFR mutation and have radiologically or clinically progressed (in the opinion of the treating physician) on osimertinib, alone or in combination with other agent(s), as their most recent line of therapy. Any number of prior lines of therapy is allowed - Participants must have a MET amplification determined by tissue-based or blood-based (circulating tumor DNA [ctDNA]) next generation sequencing (NGS) assay. MET amplifications may have been determined based on tissue submitted for testing by Foundation Medicine Inc (FMI) through the LUNGMAP screening protocol or using test results completed outside of the study. Tissue or blood must be obtained after disease progression on osimertinib (alone or in combination with another agent[s]). The testing must be done within a laboratory with Clinical Laboratory Improvement Act (CLIA), International Organization for Standardization (ISO)/Independent Ethics Committee (IEC), College of American Pathologists (CAP), or similar certification - Note: Participants previously tested for and determined to have MET amplified NSCLC, at the time of progression on osimertinib, outside of LUNGMAP, must also submit tissue for central FMI testing on the LUNGMAP screening protocol, if available - Participants must have either measurable disease or non-measurable disease documented by CT or MRI. The CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality. Measurable disease must be assessed within 28 days prior to sub-study randomization. Non-measurable disease must be assessed within 42 days prior to sub-study randomization. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form. Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to sub-study randomization to be considered measurable - Participants must have a CT with contrast or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study randomization - Participants with symptomatic CNS metastasis (brain metastases or leptomeningeal disease) must be neurologically stable and have a stable or decreasing corticosteroid requirement for at least 5 days before sub-study randomization - Participants must have recovered (=< grade 1) from any side effects of prior therapy, except for alopecia and vitiligo - Participants must be able to swallow tablets whole - Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days prior to sub-study randomization) - Hemoglobin < 9.0 g/dL (within 28 days prior to sub-study randomization) - Platelets >= 100 x 10^3/uL (within 28 days prior to sub-study randomization) - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) unless history of Gilbert's disease (within 28 days prior to sub-study randomization). Participants with history of Gilbert's disease must have total bilirubin =< 5 x institutional ULN - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN. Participants with history of liver metastasis must have AST =< 5 x ULN (within 28 days prior to sub-study randomization) - Participants must have a serum creatinine =< the IULN OR calculated creatinine clearance >= 50 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to sub-study randomization - Participants' most recent Zubrod performance status must be 0-1 and be documented within 28 days prior to sub-study randomization - Participants must have an electrocardiogram (ECG) performed, with a Fridericia's Correction Formula (QTcF) =< 470 msec, within 28 days prior to sub-study randomization. It is suggested that a local cardiologist review the QTcF intervals - Participants must have a completed medical history and physical exam within 28 days prior to sub-study randomization - Participants must have a urinalysis performed 28 days prior to sub-study randomization. Participant must have a urinary protein =< 1+ on dipstick or routine urinalysis (UA). Random analysis of urine protein with a normal value is sufficient. If urine dipstick or routine analysis indicated proteinuria >= 2+, then a 24-hour urine is to be collected and demonstrate < 2000 mg of protein in 24 hours to allow participation in the study - Participants must have an International Normalized Ratio (INR) =< 1.5 seconds above the institutional upper limit of normal (IULN) (unless receiving anticoagulation therapy) documented within 28 days to sub-study randomization. Participants must have a partial thromboplastin time (PTT) =< 5 seconds above the 'institutional upper limit of normal (IULN) (unless receiving anticoagulation therapy) documented within 28 days prior to sub-study randomization - Participants with known human immunodeficiency virus (HIV) infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load within 6 months prior to sub-study randomization - Participants must have asymptomatic serum amylase =< 2 x ULN and serum lipase =< ULN obtained within 28 days prior to sub-study randomization. Asymptomatic is defined as having no signs and/ or symptoms suggesting pancreatitis or pancreatic injury (e.g. elevated P. amylase, abnormal imaging findings of pancreas, etc.) - Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better - Participants must agree to have blood specimens submitted for circulating tumor DNA (ctDNA) - Participants must also be offered participation in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System - Note: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system - Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines - Participants with impaired decision-making capacity must not have a neurological or psychological condition that precludes their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator). For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Exclusion Criteria

  • Participants must not have received an anti-VEGF or VEGFR inhibitor or MET inhibitor - Participants must not have received any anti-cancer drug (investigational or standard of care drug, except osimertinib) within 21 days prior to sub-study randomization - Note: osimertinib may continue up to the day prior to study treatment initiation - Participants must not have received any radiation therapy within 14 days prior to sub-study randomization - Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study - Participants must not have had a major surgery within 14 days prior to sub-study randomization. Participants must have fully recovered from the effects of prior surgery in the opinion of the treating investigator - Participants must not have received a live attenuated vaccination within 28 days prior to sub-study randomization. All COVID-19 vaccines that have received Food and Drug Administration (FDA) approval or FDA emergency use authorization are acceptable - Participants must not have received strong inducers of CYP3A4 (including herbal supplements such as St. John's Wort); CYP3A4 inhibitors; CYP1A2 substrates; P-gp and BCRP substrates; sensitive substrates of MATE1 and MATE2K; or drugs that are known to prolong QT interval within 7 days prior to sub-study registration and must not be planning to use any of these throughout protocol treatment - Participants must not have uncontrolled blood pressure and hypertension within 28 days prior to sub-study randomization - Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen - Participants must not be pregnant or breastfeeding (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm A (capmatinib, osimertinib, ramucirumab)
Patients receive capmatinib PO, osimertinib PO, and ramucirumab IV on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.
  • Procedure: Biospecimen Collection
    Undergo collection of blood samples
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Drug: Capmatinib
    Given PO
    Other names:
    • INC-280
    • INC280
    • INCB 28060
    • INCB028060
    • INCB28060
  • Procedure: Computed Tomography
    Undergo CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized Tomography
    • CT
    • CT Scan
    • tomography
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
  • Drug: Osimertinib
    Given PO
    Other names:
    • AZD-9291
    • AZD9291
    • Mereletinib
    • Tagrisso
  • Biological: Ramucirumab
    Given IV
    Other names:
    • Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B
    • Cyramza
    • IMC-1121B
    • LY3009806
    • Monoclonal Antibody HGS-ETR2
Experimental
Arm B (capmatinib, osimertinib)
Patients receive capmatinib PO and osimertinib PO on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.
  • Procedure: Biospecimen Collection
    Undergo collection of blood samples
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Drug: Capmatinib
    Given PO
    Other names:
    • INC-280
    • INC280
    • INCB 28060
    • INCB028060
    • INCB28060
  • Procedure: Computed Tomography
    Undergo CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized Tomography
    • CT
    • CT Scan
    • tomography
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
  • Drug: Osimertinib
    Given PO
    Other names:
    • AZD-9291
    • AZD9291
    • Mereletinib
    • Tagrisso

Recruiting Locations

Katmai Oncology Group
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Kingman Regional Medical Center
Kingman, Arizona 86401
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas 72401
Contact:
Site Public Contact
870-936-7066
Emily.Carvell@bmhcc.org

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
Contact:
Site Public Contact
501-686-8274

PCR Oncology
Arroyo Grande, California 93420
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Sutter Auburn Faith Hospital
Auburn, California 95602
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California 94704
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Tower Cancer Research Foundation
Beverly Hills, California 90211
Contact:
Site Public Contact
towercancerresearch@toweroncology.com

Palo Alto Medical Foundation-Fremont
Fremont, California 94538
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente-Fresno
Fresno, California 93720
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

UC San Diego Moores Cancer Center
La Jolla, California 92093
Contact:
Site Public Contact
858-822-5354
cancercto@ucsd.edu

Loma Linda University Medical Center
Loma Linda, California 92354
Contact:
Site Public Contact
909-558-4050

Cedars Sinai Medical Center
Los Angeles, California 90048
Contact:
Site Public Contact
310-423-8965

Memorial Medical Center
Modesto, California 95355
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente-Oakland
Oakland, California 94611
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-Roseville
Roseville, California 95661
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Sutter Roseville Medical Center
Roseville, California 95661
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente Downtown Commons
Sacramento, California 95814
Contact:
Site Public Contact
877-642-4691
kpoct@kp.org

Sutter Medical Center Sacramento
Sacramento, California 95816
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

University of California Davis Comprehensive Cancer Center
Sacramento, California 95817
Contact:
Site Public Contact
916-734-3089

California Pacific Medical Center-Pacific Campus
San Francisco, California 94115
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente-San Francisco
San Francisco, California 94115
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Veterans Affairs Medical Center - San Francisco
San Francisco, California 94121
Contact:
Site Public Contact
415-221-4810

Kaiser Permanente-Santa Teresa-San Jose
San Jose, California 95119
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente San Leandro
San Leandro, California 94577
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Mills Health Center
San Mateo, California 94401
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser San Rafael-Gallinas
San Rafael, California 94903
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California 95051
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California 95065
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Sutter Pacific Medical Foundation
Santa Rosa, California 95403
Contact:
Site Public Contact
415-209-2683
clinicalresearch@sutterhealth.org

Kaiser Permanente-South San Francisco
South San Francisco, California 94080
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California 94086
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Torrance Memorial Physician Network - Cancer Care
Torrance, California 90505
Contact:
Site Public Contact
310-750-3300
courtney.steeneken@tmphysicians.com

Kaiser Permanente-Vallejo
Vallejo, California 94589
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Sutter Solano Medical Center/Cancer Center
Vallejo, California 94589
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente-Walnut Creek
Walnut Creek, California 94596
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

UCHealth University of Colorado Hospital
Aurora, Colorado 80045
Contact:
Site Public Contact
720-848-0650

UCHealth Memorial Hospital Central
Colorado Springs, Colorado 80909
Contact:
Site Public Contact
719-365-2406

Memorial Hospital North
Colorado Springs, Colorado 80920
Contact:
Site Public Contact
719-364-6700

Poudre Valley Hospital
Fort Collins, Colorado 80524
Contact:
Site Public Contact
970-297-6150

Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado 80528
Contact:
Site Public Contact
protocols@swog.org

UCHealth Greeley Hospital
Greeley, Colorado 80631
Contact:
Site Public Contact
protocols@swog.org

UCHealth Lone Tree Health Center
Lone Tree, Colorado 80124
Contact:
Site Public Contact
protocols@swog.org

Medical Center of the Rockies
Loveland, Colorado 80538
Contact:
Site Public Contact
970-203-7083

Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut 06418
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center-Fairfield
Fairfield, Connecticut 06824
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Glastonbury
Glastonbury, Connecticut 06033
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut 06830
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut 06437
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut 06105
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Yale University
New Haven, Connecticut 06520
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Yale-New Haven Hospital North Haven Medical Center
North Haven, Connecticut 06473
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital-Orange Care Center
Orange, Connecticut 06477
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Long Ridge
Stamford, Connecticut 06902
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital-Torrington Care Center
Torrington, Connecticut 06790
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut 06611
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital-Waterbury Care Center
Waterbury, Connecticut 06708
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut 06385
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Bayhealth Hospital Kent Campus
Dover, Delaware 19901
Contact:
Site Public Contact
302-674-4401
clinical_trials@bayhealth.org

Bayhealth Hospital Sussex Campus
Milford, Delaware 19963
Contact:
Site Public Contact
302-674-4401
clinical_trials@bayhealth.org

Kaiser Permanente-Capitol Hill Medical Center
Washington D.C., District of Columbia 20002
Contact:
Site Public Contact
240-632-4285
Charmaine.A.Mckie@kp.org

Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida 33021
Contact:
Site Public Contact
954-265-1847
OHR@mhs.net

Memorial Hospital West
Pembroke Pines, Florida 33028
Contact:
Site Public Contact
954-265-4325

Moffitt Cancer Center
Tampa, Florida 33612
Contact:
Site Public Contact
800-679-0775
ClinicalTrials@moffitt.org

University Cancer and Blood Center LLC
Athens, Georgia 30607
Contact:
Site Public Contact
research@universitycancer.com

Emory University Hospital Midtown
Atlanta, Georgia 30308
Contact:
Site Public Contact
888-946-7447

Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
Contact:
Site Public Contact
404-778-1868

Northside Hospital
Atlanta, Georgia 30342
Contact:
Site Public Contact
404-303-3355
ClinicalTrials@northside.com

Northside Hospital - Duluth
Duluth, Georgia 30096
Contact:
Site Public Contact
404-303-3355
Clinical.trials@northside.com

Northeast Georgia Medical Center-Gainesville
Gainesville, Georgia 30501
Contact:
Site Public Contact
770-219-8800
cancerpatient.navigator@nghs.com

Northside Hospital - Gwinnett
Lawrenceville, Georgia 30046
Contact:
Site Public Contact
404-303-3355
Clinical.trials@northside.com

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia 31405
Contact:
Site Public Contact
912-819-5704
underberga@sjchs.org

Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-524-6115
i.webster@hawaiicancercare.com

Queen's Cancer Cenrer - POB I
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-532-0315

Queen's Medical Center
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-545-8548

Queen's Cancer Center - Kuakini
Honolulu, Hawaii 96817
Contact:
Site Public Contact
808-531-8521

Hawaii Cancer Care - Westridge
‘Aiea, Hawaii 96701
Contact:
Site Public Contact
808-539-2273
info@hawaiicancercare.com

Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho 83706
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho 83605
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho 83814
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho 83687
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho 83854
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho 83864
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Advocate Good Shepherd Hospital
Barrington, Illinois 60010
Contact:
Site Public Contact
847-842-4847

Illinois CancerCare-Bloomington
Bloomington, Illinois 61704
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Canton
Canton, Illinois 61520
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Carthage
Carthage, Illinois 62321
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Centralia Oncology Clinic
Centralia, Illinois 62801
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern University
Chicago, Illinois 60611
Contact:
Site Public Contact
312-695-1301
cancer@northwestern.edu

Rush MD Anderson Cancer Center
Chicago, Illinois 60612
Contact:
Site Public Contact
312-226-2371
Cancer_Studies@rush.edu

Advocate Illinois Masonic Medical Center
Chicago, Illinois 60657
Contact:
Site Public Contact
773-296-5360

AMG Crystal Lake - Oncology
Crystal Lake, Illinois 60014
Contact:
Site Public Contact
630-929-6129
advocateresearch@advocate.com

Carle at The Riverfront
Danville, Illinois 61832
Contact:
Site Public Contact
800-446-5532
Research@Carle.com

Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Decatur Memorial Hospital
Decatur, Illinois 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois 60115
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Illinois CancerCare-Dixon
Dixon, Illinois 61021
Contact:
Site Public Contact
815-285-7800

Advocate Good Samaritan Hospital
Downers Grove, Illinois 60515
Contact:
Site Public Contact
630-275-1270
Barbara.barhamand@advocatehealth.com

Carle Physician Group-Effingham
Effingham, Illinois 62401
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Crossroads Cancer Center
Effingham, Illinois 62401
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Advocate Sherman Hospital
Elgin, Illinois 60123
Contact:
Site Public Contact
847-429-2907

Illinois CancerCare-Eureka
Eureka, Illinois 61530
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Galesburg
Galesburg, Illinois 61401
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern Medicine Cancer Center Delnor
Geneva, Illinois 60134
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Northwestern Medicine Glenview Outpatient Center
Glenview, Illinois 60026
Contact:
Site Public Contact
312-695-1102

Northwestern Medicine Grayslake Outpatient Center
Grayslake, Illinois 60030
Contact:
Site Public Contact
312-695-1102

Advocate South Suburban Hospital
Hazel Crest, Illinois 60429
Contact:
Site Public Contact
708-799-9995

Edward Hines Jr VA Hospital
Hines, Illinois 60141
Contact:
Site Public Contact
708-202-8387

Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois 61443
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois 60045
Contact:
Site Public Contact
cancertrials@northwestern.edu

AMG Libertyville - Oncology
Libertyville, Illinois 60048
Contact:
Site Public Contact
630-929-6129
advocateresearch@advocatehealth.com

Condell Memorial Hospital
Libertyville, Illinois 60048
Contact:
Site Public Contact
630-929-6129
advocateresearch@advocatehealth.com

Illinois CancerCare-Macomb
Macomb, Illinois 61455
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois 61938
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Loyola University Medical Center
Maywood, Illinois 60153
Contact:
Site Public Contact
708-226-4357

Cancer Care Center of O'Fallon
O'Fallon, Illinois 62269
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Advocate Christ Medical Center
Oak Lawn, Illinois 60453-2699
Contact:
Site Public Contact
800-323-8622

Rush MD Anderson Cancer Center at Rush Oak Park
Oak Park, Illinois 60304
Contact:
Site Public Contact
312-226-2371
Cancer_Studies@rush.edu

Northwestern Medicine Orland Park
Orland Park, Illinois 60462
Contact:
Site Public Contact
nctnprogram_rhlccc@northwestern.edu

Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois 61350
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Advocate Lutheran General Hospital
Park Ridge, Illinois 60068
Contact:
Site Public Contact
847-384-3621

Illinois CancerCare-Pekin
Pekin, Illinois 61554
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peoria
Peoria, Illinois 61615
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peru
Peru, Illinois 61354
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Princeton
Princeton, Illinois 61356
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

OSF Saint Anthony Medical Center
Rockford, Illinois 61108
Contact:
Site Public Contact
815-227-2633

Southern Illinois University School of Medicine
Springfield, Illinois 62702
Contact:
Site Public Contact
217-545-7929

Springfield Clinic
Springfield, Illinois 62702
Contact:
Site Public Contact
800-444-7541

Springfield Memorial Hospital
Springfield, Illinois 62781
Contact:
Site Public Contact
217-528-7541
pallante.beth@mhsil.com

Carle Cancer Center
Urbana, Illinois 61801
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois 60555
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Illinois CancerCare - Washington
Washington, Illinois 61571
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa 50023
Contact:
Site Public Contact
515-241-3305

UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa 50325
Contact:
Site Public Contact
515-241-3305

Iowa Methodist Medical Center
Des Moines, Iowa 50309
Contact:
Site Public Contact
515-241-6727

UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa 50309
Contact:
Site Public Contact
515-241-3305

Mercy Medical Center - Des Moines
Des Moines, Iowa 50314
Contact:
Site Public Contact
515-358-6613
cancerresearch@mercydesmoines.org

UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, Iowa 50314
Contact:
Site Public Contact
515-241-3305

UI Health Care Mission Cancer and Blood - Waukee Clinic
Waukee, Iowa 50263
Contact:
Site Public Contact
515-241-3305

University of Kansas Clinical Research Center
Fairway, Kansas 66205
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

HaysMed
Hays, Kansas 67601
Contact:
Site Public Contact
785-623-5774

University of Kansas Cancer Center
Kansas City, Kansas 66160
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Lawrence Memorial Hospital
Lawrence, Kansas 66044
Contact:
Site Public Contact
785-505-2800
Stephanie.Norris@LMH.ORG

The University of Kansas Cancer Center - Olathe
Olathe, Kansas 66061
Contact:
Site Public Contact
913-588-1569
OlatheCCResearch@kumc.edu

University of Kansas Cancer Center-Overland Park
Overland Park, Kansas 66210
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas 66211
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Salina Regional Health Center
Salina, Kansas 67401
Contact:
Site Public Contact
785-452-7038
mleepers@srhc.com

University of Kansas Health System Saint Francis Campus
Topeka, Kansas 66606
Contact:
Site Public Contact
785-295-8000

University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas 66205
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kentucky/Markey Cancer Center
Lexington, Kentucky 40536
Contact:
Site Public Contact
859-257-3379

Lafayette Family Cancer Center-EMMC
Brewer, Maine 04412
Contact:
Site Public Contact
800-987-3005

Kaiser Permanente-Woodlawn Medical Center
Baltimore, Maryland 21244
Contact:
Site Public Contact
240-632-4285
Charmaine.A.Mckie@kp.org

UPMC Western Maryland
Cumberland, Maryland 21502
Contact:
Site Public Contact
240-964-1400

Kaiser Permanente-Gaithersburg Medical Center
Gaithersburg, Maryland 20879
Contact:
Site Public Contact
240-632-4285
Charmaine.A.Mckie@kp.org

Kaiser Permanente - Largo Medical Center
Largo, Maryland 20774
Contact:
Site Public Contact
240-632-4285
Charmaine.A.Mckie@kp.org

Kaiser Permanente Lutherville - Timonium Medical Center
Lutherville, Maryland 21093
Contact:
Site Public Contact
240-632-4285
Charmaine.A.Mckie@kp.org

UMass Memorial Medical Center - University Campus
Worcester, Massachusetts 01655
Contact:
Site Public Contact
508-856-3216
cancer.research@umassmed.edu

Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan 48106
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health Medical Center - Brighton
Brighton, Michigan 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health Medical Center - Canton
Canton, Michigan 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Chelsea Hospital
Chelsea, Michigan 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Henry Ford Hospital
Detroit, Michigan 48202
Contact:
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

Cancer Hematology Centers - Flint
Flint, Michigan 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

Genesys Hurley Cancer Institute
Flint, Michigan 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

Hurley Medical Center
Flint, Michigan 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

University of Michigan Health - Sparrow Lansing
Lansing, Michigan 48912
Contact:
Site Public Contact
517-364-3712
harsha.trivedi@umhsparrow.org

Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan 48154
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Henry Ford Medical Center-Columbus
Novi, Michigan 48377
Contact:
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, Michigan 48341
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

MyMichigan Medical Center Saginaw
Saginaw, Michigan 48601
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

MyMichigan Medical Center Tawas
Tawas City, Michigan 48764
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan 48322
Contact:
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

Huron Gastroenterology PC
Ypsilanti, Michigan 48106
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, Michigan 48197
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Sanford Joe Lueken Cancer Center
Bemidji, Minnesota 56601
Contact:
Site Public Contact
218-333-5000
OncologyClinicalTrialsFargo@sanfordhealth.org

Mercy Hospital
Coon Rapids, Minnesota 55433
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Essentia Health - Deer River Clinic
Deer River, Minnesota 56636
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health Cancer Center
Duluth, Minnesota 55805
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Fairview Southdale Hospital
Edina, Minnesota 55435
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Essentia Health Hibbing Clinic
Hibbing, Minnesota 55746
Contact:
Site Public Contact
218-786-3308

Abbott-Northwestern Hospital
Minneapolis, Minnesota 55407
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota 55416
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Regions Hospital
Saint Paul, Minnesota 55101
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

United Hospital
Saint Paul, Minnesota 55102
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Essentia Health Sandstone
Sandstone, Minnesota 55072
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health Virginia Clinic
Virginia, Minnesota 55792
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Ridgeview Medical Center
Waconia, Minnesota 55387
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippi 39705
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Cancer Center-Grenada
Grenada, Mississippi 38901
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

University of Mississippi Medical Center
Jackson, Mississippi 39216
Contact:
Site Public Contact
601-815-6700

Baptist Memorial Hospital and Cancer Center-Union County
New Albany, Mississippi 38652
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippi 38655
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven, Mississippi 38671
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Saint Francis Medical Center
Cape Girardeau, Missouri 63703
Contact:
Site Public Contact
573-334-2230
sfmc@sfmc.net

Parkland Health Center - Farmington
Farmington, Missouri 63640
Contact:
Site Public Contact
314-996-5569

University Health Truman Medical Center
Kansas City, Missouri 64108
Contact:
Site Public Contact
816-404-4375

University of Kansas Cancer Center - Briarcliff
Kansas City, Missouri 64116
Contact:
Site Public Contact
913-588-3671

University of Kansas Cancer Center - North
Kansas City, Missouri 64154
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri 64064
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri 63670
Contact:
Site Public Contact
314-996-5569

Mercy Hospital South
St Louis, Missouri 63128
Contact:
Site Public Contact
314-525-6042
Danielle.Werle@mercy.net

Missouri Baptist Medical Center
St Louis, Missouri 63131
Contact:
Site Public Contact
314-996-5569

Mercy Hospital Saint Louis
St Louis, Missouri 63141
Contact:
Site Public Contact
314-251-7066

Missouri Baptist Sullivan Hospital
Sullivan, Missouri 63080
Contact:
Site Public Contact
314-996-5569

BJC Outpatient Center at Sunset Hills
Sunset Hills, Missouri 63127
Contact:
Site Public Contact
314-996-5569

Community Hospital of Anaconda
Anaconda, Montana 59711
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Billings Clinic Cancer Center
Billings, Montana 59101
Contact:
Site Public Contact
800-996-2663
research@billingsclinic.org

Bozeman Health Deaconess Hospital
Bozeman, Montana 59715
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Benefis Sletten Cancer Institute
Great Falls, Montana 59405
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Logan Health Medical Center
Kalispell, Montana 59901
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Community Medical Center
Missoula, Montana 59804
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

OptumCare Cancer Care at Seven Hills
Henderson, Nevada 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

OptumCare Cancer Care at Charleston
Las Vegas, Nevada 89102
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada 89148
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire 03301
Contact:
Site Public Contact
603-224-2556

Solinsky Center for Cancer Care
Manchester, New Hampshire 03103
Contact:
Site Public Contact
800-339-6484

Virtua Samson Cancer Center
Moorestown, New Jersey 08057
Contact:
Site Public Contact
856-206-4721
nctn@pennmedicine.upenn.edu

Virtua Voorhees
Voorhees Township, New Jersey 08043
Contact:
Site Public Contact
856-247-7395
nctn@pennmedicine.upenn.edu

University of New Mexico Cancer Center
Albuquerque, New Mexico 87106
Contact:
Site Public Contact
505-925-0348
HSC-ClinicalTrialInfo@salud.unm.edu

University of Rochester
Rochester, New York 14642
Contact:
Site Public Contact
585-275-5830

Montefiore Medical Center-Einstein Campus
The Bronx, New York 10461
Contact:
Site Public Contact
718-379-6866
eskwak@montefiore.org

Montefiore Medical Center - Moses Campus
The Bronx, New York 10467
Contact:
Site Public Contact
718-379-6866
eskwak@montefiore.org

James J Peters VA Medical Center
The Bronx, New York 10468
Contact:
Site Public Contact
718-584-9000
kl2965@cumc.columbia.edu

Rex Hematology Oncology Associates-Cary
Cary, North Carolina 27518
Contact:
Site Public Contact
919-784-2500
CancCtrOncologyClinicalResearch@unchealth.unc.edu

Durham VA Medical Center
Durham, North Carolina 27705
Contact:
Site Public Contact
919-286-0411
VHADURcancertrials@va.gov

Rex Hematology Oncology Associates-Garner
Garner, North Carolina 27529
Contact:
Site Public Contact
919-784-2500
CancCtrOncologyClinicalResearch@unchealth.unc.edu

UNC Rex Healthcare
Raleigh, North Carolina 27607
Contact:
Site Public Contact
919-784-2500
CancCtrOncologyClinicalResearch@unchealth.unc.edu

UNC Rex Cancer Center of Wakefield
Raleigh, North Carolina 27614
Contact:
Site Public Contact
919-784-2500
CancCtrOncologyClinicalResearch@unchealth.unc.edu

Sanford Bismarck Medical Center
Bismarck, North Dakota 58501
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Broadway Medical Center
Fargo, North Dakota 58122
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Roger Maris Cancer Center
Fargo, North Dakota 58122
Contact:
Site Public Contact
701-234-6161
OncologyClinicalTrialsFargo@sanfordhealth.org

Strecker Cancer Center-Belpre
Belpre, Ohio 45714
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Cleveland Clinic Mercy Hospital
Canton, Ohio 44708
Contact:
Site Public Contact
888-293-4673

Aultman Health Foundation
Canton, Ohio 44710
Contact:
Site Public Contact
330-363-7274
ClinicalReserachDept@aultman.com

Miami Valley Hospital South
Centerville, Ohio 45459
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Adena Regional Medical Center
Chillicothe, Ohio 45601
Contact:
Site Public Contact
877-779-7585
Jeffh@columbusccop.org

Mount Carmel East Hospital
Columbus, Ohio 43213
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

The Mark H Zangmeister Center
Columbus, Ohio 43219
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Miami Valley Hospital
Dayton, Ohio 45409
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Premier Blood and Cancer Center
Dayton, Ohio 45409
Contact:
Site Public Contact
937-276-8320

Miami Valley Hospital North
Dayton, Ohio 45415
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio 45005-1066
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Miami Valley Cancer Care and Infusion
Greenville, Ohio 45331
Contact:
Site Public Contact
937-569-7515

Mount Carmel Grove City Hospital
Grove City, Ohio 43123
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Fairfield Medical Center
Lancaster, Ohio 43130
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Memorial Hospital
Marysville, Ohio 43040
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Knox Community Hospital
Mount Vernon, Ohio 43050
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Licking Memorial Hospital
Newark, Ohio 43055
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Mercy Health - Perrysburg Hospital
Perrysburg, Ohio 43551
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Southern Ohio Medical Center
Portsmouth, Ohio 45662
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Springfield Regional Cancer Center
Springfield, Ohio 45504
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Trinity's Tony Teramana Cancer Center
Steubenville, Ohio 43952
Contact:
Site Public Contact
888-874-7000

ProMedica Flower Hospital
Sylvania, Ohio 43560
Contact:
Site Public Contact
419-824-1842
PCIOncResearch@promedica.org

Mercy Health - Saint Anne Hospital
Toledo, Ohio 43623
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Upper Valley Medical Center
Troy, Ohio 45373
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Saint Ann's Hospital
Westerville, Ohio 43081
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Genesis Healthcare System Cancer Care Center
Zanesville, Ohio 43701
Contact:
Site Public Contact
614-488-2745
Jeffh@columbusccop.org

Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma 73505
Contact:
Site Public Contact
877-231-4440

University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73104
Contact:
Site Public Contact
405-271-8777
ou-clinical-trials@ouhsc.edu

Providence Newberg Medical Center
Newberg, Oregon 97132
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Saint Alphonsus Cancer Care Center-Ontario
Ontario, Oregon 97914
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Providence Willamette Falls Medical Center
Oregon City, Oregon 97045
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Portland Medical Center
Portland, Oregon 97213
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Saint Vincent Medical Center
Portland, Oregon 97225
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Kaiser Permanente Northwest
Portland, Oregon 97227
Contact:
Site Public Contact
503-335-2400
information@kpchr.org

Oregon Health and Science University
Portland, Oregon 97239
Contact:
Site Public Contact
503-494-1080
trials@ohsu.edu

UPMC Altoona
Altoona, Pennsylvania 16601
Contact:
Site Public Contact
protocols@swog.org

UPMC-Heritage Valley Health System Beaver
Beaver, Pennsylvania 15009
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC Hillman Cancer Center at Butler Health System
Butler, Pennsylvania 16001
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Carlisle Regional Cancer Center
Carlisle, Pennsylvania 17015
Contact:
Site Public Contact
protocols@swog.org

WellSpan Medical Oncology and Hematology
Chambersburg, Pennsylvania 17201
Contact:
Site Public Contact
717-217-6020

UPMC Hillman Cancer Center - Passavant - Cranberry
Cranberry Township, Pennsylvania 16066
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Geisinger Medical Center
Danville, Pennsylvania 17822
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Geisinger Cancer Center Dickson City
Dickson City, Pennsylvania 18519
Contact:
Site Public Contact
877-204-6081
hemoncctrials@geisinger.edu

Ephrata Cancer Center
Ephrata, Pennsylvania 17522
Contact:
Site Public Contact
717-721-4840

UPMC Hillman Cancer Center Erie
Erie, Pennsylvania 16505
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC Cancer Center at UPMC Horizon
Farrell, Pennsylvania 16121
Contact:
Site Public Contact
protocols@swog.org

Adams Cancer Center
Gettysburg, Pennsylvania 17325
Contact:
Site Public Contact
877-441-7957

UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania 15601
Contact:
Site Public Contact
724-838-1900

UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania 17109
Contact:
Site Public Contact
717-724-6765
klitchfield@PINNACLEHEALTH.org

IRMC Cancer Center
Indiana, Pennsylvania 15701
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC-Johnstown/John P. Murtha Regional Cancer Center
Johnstown, Pennsylvania 15901
Contact:
Site Public Contact
814-534-4724

Sechler Family Cancer Center
Lebanon, Pennsylvania 17042
Contact:
Site Public Contact
717-741-8303
doxenberg@wellspan.org

Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania 17837
Contact:
Site Public Contact
570-374-8555
HemonCCTrials@geisinger.edu

UPMC Cancer Center at UPMC McKeesport
McKeesport, Pennsylvania 15132
Contact:
Site Public Contact
412-647-8073

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Mechanicsburg, Pennsylvania 17050
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC Hillman Cancer Center - Monroeville
Monroeville, Pennsylvania 15146
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC Hillman Cancer Center in Coraopolis
Moon Township, Pennsylvania 15108
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC Hillman Cancer Center - Part of Frick Hospital
Mount Pleasant, Pennsylvania 15666
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Arnold Palmer Cancer Center Medical Oncology Norwin
N. Huntingdon, Pennsylvania 15642
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC Cancer Center-Natrona Heights
Natrona Heights, Pennsylvania 15065
Contact:
Site Public Contact
724-230-3030

UPMC Hillman Cancer Center - New Castle
New Castle, Pennsylvania 16105
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania 19104
Contact:
Site Public Contact
215-349-8245
PMCancerResearch@pennmedicine.upenn.edu

UPMC-Saint Margaret
Pittsburgh, Pennsylvania 15215
Contact:
Site Public Contact
412-784-4900

UPMC-Mercy Hospital
Pittsburgh, Pennsylvania 15219
Contact:
Site Public Contact
800-533-8762

University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
Contact:
Site Public Contact
412-647-8073

UPMC-Passavant Hospital
Pittsburgh, Pennsylvania 15237
Contact:
Site Public Contact
412-367-6454

UPMC-Saint Clair Hospital Cancer Center
Pittsburgh, Pennsylvania 15243
Contact:
Site Public Contact
412-502-3920

Community Medical Center
Scranton, Pennsylvania 18510
Contact:
Site Public Contact
570-703-4768
HemonCCTrials@geisinger.edu

UPMC Cancer Center at UPMC Northwest
Seneca, Pennsylvania 16346
Contact:
Site Public Contact
814-676-7900

UPMC Cancer Center-Uniontown
Uniontown, Pennsylvania 15401
Contact:
Site Public Contact
protocols@swog.org

UPMC Cancer Center-Washington
Washington, Pennsylvania 15301
Contact:
Site Public Contact
protocols@swog.org

UPMC West Mifflin-Cancer Center Jefferson
West Mifflin, Pennsylvania 15122
Contact:
Site Public Contact
412-653-8100

Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania 18711
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Divine Providence Hospital
Williamsport, Pennsylvania 17754
Contact:
Site Public Contact
protocols@swog.org

WellSpan Health-York Cancer Center
York, Pennsylvania 17403
Contact:
Site Public Contact
877-441-7957

UPMC Memorial
York, Pennsylvania 17408
Contact:
Site Public Contact
717-724-6760

Smilow Cancer Hospital Care Center - Westerly
Westerly, Rhode Island 02891
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

AnMed Health Cancer Center
Anderson, South Carolina 29621
Contact:
Site Public Contact
864-512-4651
rhonda.ballew@anmedhealth.org

Saint Joseph's/Candler - Bluffton Campus
Bluffton, South Carolina 29910
Contact:
Site Public Contact
912-819-5704
underberga@sjchs.org

Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina 29316
Contact:
Site Public Contact
864-522-4317
Kim.Williams3@prismahealth.org

Ralph H Johnson VA Medical Center
Charleston, South Carolina 29401
Contact:
Site Public Contact
843-789-7020
ashley.salvo@va.gov

Medical University of South Carolina
Charleston, South Carolina 29425
Contact:
Site Public Contact
843-792-9321
hcc-clinical-trials@musc.edu

Prisma Health Cancer Institute - Easley
Easley, South Carolina 29640
Contact:
Site Public Contact
864-522-4317
Kim.Williams3@prismahealth.org

Prisma Health Cancer Institute - Butternut
Greenville, South Carolina 29605
Contact:
Site Public Contact
864-522-4317
Kim.Williams3@prismahealth.org

Prisma Health Cancer Institute - Faris
Greenville, South Carolina 29605
Contact:
Site Public Contact
864-522-4317
Kim.Williams3@prismahealth.org

Prisma Health Greenville Memorial Hospital
Greenville, South Carolina 29605
Contact:
Site Public Contact
864-522-4317
Kim.Williams3@prismahealth.org

Prisma Health Cancer Institute - Eastside
Greenville, South Carolina 29615
Contact:
Site Public Contact
864-522-4317
Kim.Williams3@prismahealth.org

Prisma Health Cancer Institute - Greer
Greer, South Carolina 29650
Contact:
Site Public Contact
864-522-4317
Kim.Williams3@prismahealth.org

Prisma Health Cancer Institute - Seneca
Seneca, South Carolina 29672
Contact:
Site Public Contact
864-522-4317
Kim.Williams3@prismahealth.org

Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota 57104
Contact:
Site Public Contact
605-312-3320
OncologyClinicTrialsSF@sanfordhealth.org

Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota 57117-5134
Contact:
Site Public Contact
605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org

Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, Tennessee 38017
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee 38120
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

The Don and Sybil Harrington Cancer Center
Amarillo, Texas 79106
Contact:
Site Public Contact
806-212-1985
Gina.Cravey@bsahs.org

Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah 84112
Contact:
Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu

Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners, Vermont 05602
Contact:
Site Public Contact
802-225-5400

University of Virginia Cancer Center
Charlottesville, Virginia 22908
Contact:
Site Public Contact
434-243-6303
uvacancertrials@hscmail.mcc.virginia.edu

Kaiser Permanente Tysons Corner Medical Center
McLean, Virginia 22102
Contact:
Site Public Contact
240-632-4285
Charmaine.A.Mckie@kp.org

Kaiser Permanente-Caton Hill Medical Center
Woodbridge, Virginia 22192
Contact:
Site Public Contact
240-632-4285
Charmaine.A.Mckie@kp.org

FHCC Overlake
Bellevue, Washington 98004
Contact:
Site Public Contact
425-454-2148

FHCC at EvergreenHealth
Kirkland, Washington 98034
Contact:
Site Public Contact
425-899-6000

Valley Medical Center
Renton, Washington 98055
Contact:
Site Public Contact
425-228-3440
research@valleymed.org

Fred Hutchinson Cancer Center
Seattle, Washington 98109
Contact:
Site Public Contact
800-804-8824

Swedish Medical Center-First Hill
Seattle, Washington 98122
Contact:
Site Public Contact
206-215-2343
PCRC-NCORP@Swedish.org

FHCC at Northwest Hospital
Seattle, Washington 98133
Contact:
Site Public Contact
206-606-5800

University of Washington Medical Center - Montlake
Seattle, Washington 98195
Contact:
Site Public Contact
800-804-8824

Edwards Comprehensive Cancer Center
Huntington, West Virginia 25701
Contact:
Site Public Contact
304-399-6566
Christina.Cole@chhi.org

Langlade Hospital and Cancer Center
Antigo, Wisconsin 54409
Contact:
Site Public Contact
715-623-9869
Juli.Alford@aspirus.org

Duluth Clinic Ashland
Ashland, Wisconsin 54806
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin 53105
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin 54701
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Aurora Health Care Germantown Health Center
Germantown, Wisconsin 53022
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora Cancer Care-Grafton
Grafton, Wisconsin 53024
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora BayCare Medical Center
Green Bay, Wisconsin 54311
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin 53142
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Gundersen Lutheran Medical Center
La Crosse, Wisconsin 54601
Contact:
Site Public Contact
608-775-2385
cancerctr@gundersenhealth.org

Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin 54143
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Marshfield Medical Center-Marshfield
Marshfield, Wisconsin 54449
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Aspirus Medford Hospital
Medford, Wisconsin 54451
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin 53209
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin 53215
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Medical College of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Site Public Contact
414-805-3666

Aurora Sinai Medical Center
Milwaukee, Wisconsin 53233
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Marshfield Medical Center - Minocqua
Minocqua, Wisconsin 54548
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin 54904
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora Cancer Care-Racine
Racine, Wisconsin 53406
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aspirus Cancer Care - James Beck Cancer Center
Rhinelander, Wisconsin 54501
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin 54868
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin 53081
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aspirus Cancer Care - Stevens Point
Stevens Point, Wisconsin 54481
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Marshfield Medical Center-River Region at Stevens Point
Stevens Point, Wisconsin 54482
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Aurora Medical Center in Summit
Summit, Wisconsin 53066
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin 54241
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aspirus Regional Cancer Center
Wausau, Wisconsin 54401
Contact:
Site Public Contact
877-405-6866

Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin 53226
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora West Allis Medical Center
West Allis, Wisconsin 53227
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Marshfield Medical Center - Weston
Weston, Wisconsin 54476
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids, Wisconsin 54494
Contact:
Site Public Contact
715-422-7718

More Details

NCT ID
NCT05642572
Status
Recruiting
Sponsor
SWOG Cancer Research Network

Detailed Description

PRIMARY OBJECTIVE: I. To compare investigator-assessed progression-free survival (IA-PFS) between participants with EGFR mutated, MET amplified non-small cell lung cancer (NSCLC) randomized to INC280 (capmatinib) and osimertinib with or without ramucirumab. SECONDARY OBJECTIVES: I. To evaluate if the combination of INC280 (capmatinib), osimertinib and ramucirumab or INC280 (capmatinib) and osimertinib during the first cycle of treatment has an acceptable toxicity rate. II. To evaluate the frequency and severity of toxicities within the arms. III. To compare IA-PFS between the arms, in the subset of participants with centrally-confirmed MET amplification in tissue. IV. To compare IA-PFS between the arms, in the subset of participants with centrally-confirmed MET amplification based on circulating tumor deoxyribonucleic acid (ctDNA). V. To compare IA-PFS between the randomized arms in the subsets of participants with and without history of brain metastases. VI. To compare the objective response rate (ORR) (confirmed and unconfirmed, complete and partial) between the arms among participants with measurable disease at baseline. VII. To compare overall survival between the arms. VIII. To compare IA-PFS between the randomized arms in the subsets of patients who have received only 1 prior line of therapy and those who have received 2 or more prior lines of therapy. IX. To evaluate duration of response among responders within each arm. TRANSLATIONAL MEDICINE OBJECTIVES: I. To collect, process, and bank cell-free deoxyribonucleic acid (ctDNA) prior to treatment (Cycle 1 Day 1), Cycle 1 Day 15, Cycle 3 Day 1, and first progression for future development of a proposal to evaluate comprehensive next-generation sequencing of circulating tumor deoxyribonucleic acid (ctDNA). II. To establish a tissue/blood repository from participants with refractory non-small cell lung cancer (NSCLC). OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive capmatinib orally (PO), osimertinib PO, and ramucirumab intravenously (IV) on study. Patients also undergo computed tomography (CT) scan or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial. ARM B: Patients receive capmatinib PO and osimertinib PO on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.